More recently, a multicenter retrospective study showed limited activity in patients with stage III unresectable NSCLC with driver genomic alterations treated with durvalumab (PD-L1 inhibitor) after chemoradiotherapy, especially in the ALK rearrangement subgroup. The gene discussed is ALK; the disease is non-small cell lung carcinoma.